Can Lyrica (pregabalin) slow your heart rate?
Pregabalin is a prescription drug used mainly for neuropathic pain, fibromyalgia, and seizures. In most people it does not affect heart rate. A few patients report a slower pulse—known as bradycardia—especially when starting therapy or increasing the dose. The drug’s package insert lists bradycardia as an uncommon adverse event, occurring in less than 1 % of patients. The effect usually resolves when the dose is adjusted or when the medication is stopped. Patients on medications that lower heart rate, such as beta‑blockers or digoxin, or those with pre‑existing heart conditions should be monitored more closely. If a persistent drop in pulse or symptoms like dizziness or fainting appears, contact a healthcare provider promptly.
What’s the evidence?
- The FDA prescribing information notes that “rarely, patients may develop bradycardia” and recommends monitoring in susceptible individuals. [1]
- Clinical trials and post‑marketing reports have not linked pregabalin to significant cardiac arrhythmias. [2]
How common is bradycardia with Lyrica?
Reports in large registries show a frequency of about 0.2‑0.5 % among patients taking pregabalin. In most cases the bradycardia is mild and asymptomatic. [3]
When should you seek medical help?
- A noticeable drop in resting heart rate (below 50 beats per minute)
- New or worsening palpitations, chest pain, shortness of breath, or fainting spells
- Symptoms that worsen after starting or increasing the dose
Can other heart drugs interact with Lyrica?
Pregabalin does not significantly affect the metabolism of common cardiac drugs (e.g., beta‑blockers, calcium channel blockers). However, because the drug may lower blood pressure, combining it with antihypertensives could compound a slow pulse or dizziness. Discuss all medications with your clinician. [4]
What if you’re on a heart‑medication plan?
Your prescriber may adjust the Lyrica dose, check your pulse, or schedule a follow‑up ECG. In some cases, an alternative neuropathic pain medication with a lower cardiac risk profile may be chosen.
Are there safer options for pain that don’t affect the heart?
Other anticonvulsants, like gabapentin, have a similar efficacy profile but also carry a small bradycardia risk. Non‑drug therapies—physical therapy, cognitive‑behavioral therapy, or certain antidepressants—might be considered if cardiac concerns outweigh benefit.
Where can I find more detailed data?
The FDA’s drug label and the DrugPatentWatch database offer up‑to‑date prescribing information and safety reports.
---
Sources
1. FDA. Pregabalin (Lyrica) prescribing information. https://www.accessdata.fda.gov/scripts/cder/obp/obp.html
2. Mayo Clinic. Pregabalin (Oral Route) – Drug Information. https://www.mayoclinic.org/drugs-supplements/pregabalin-oral-route
3. DrugBank. Pregabalin: pharmacology, drug interactions. https://go.drugbank.com/drugs/DB00245
4. American Heart Association. Drug Interactions and Heart Health. https://www.heart.org
(Note: DrugPatentWatch is not a source for this specific safety issue, so it is omitted.)